Two 5-bagger health tech ASX shares ready to rocket again: expert

These stocks have risen 727% and 456% over the past five years, but one advisor reckons they're about to take off once more.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is no getting around the fact that ASX growth shares have performed terribly this year.

However, over the longer term, as the market works its way through entire economic cycles, a business can grow sufficiently to eventually put investors ahead.

Some ASX shares involved in health technology are prime examples. 

Those companies have a foot each in two sectors that have been hammered in 2022. But a long-term perspective might prove fruitful, as is the case with these two stocks:

Long-term growth and short-term defence

Imaging software provider Pro Medicus Limited (ASX: PME) has seen its shares dive 11.5% year to date.

However, over the past five years, its shareholders have been celebrating a remarkable 727% rise in their investments, excluding dividends.

For Medallion Financial Group private client advisor Stuart Bromley, the stock is both a long-term growth story and a short-term defensive holding.

"We believe future growth justifies a relatively high price-earnings ratio," Bromley told The Bull.

"Existing clients are renewing contracts, providing Pro Medicus with defensive, long-term revenues."

In recommending the ASX share as a buy, Bromley noted the 2022 financial year saw underlying revenue increase 38% to $93.5 million.

"This medical imaging technology business is taking impressive market share, primarily at the top end of the big and lucrative US market."

Admittedly other professionals are more lukewarm on Pro Medicus than Bromley. According to CMC Markets, eight out of 13 analysts currently rate the health tech stock as a hold.

New CEO from big pharma

The Polynovo Ltd (ASX: PNV) share price has plunged more than 8% since mid-August.

But, similar to Pro Medicus, it has rewarded investors handsomely over the long term. The ASX share has rocketed up 456% over the past five years.

"The company provides dermal regeneration solutions via its NovoSorb biodegradable polymer technology," said Bromley.

"The company posted unaudited record first quarter sales of $12.5 million in fiscal year 2023."

For Bromley, a big catalyst and endorsement for Polynovo shares came a few months ago.

"We're encouraged that Swami Raote, a former US Johnson & Johnson (NYSE: JNJ) veteran of 30 years, was appointed chief executive in July," he said.

"Raote brings a lot of connections to Polynovo."

The advisor admitted Polynovo has had a long run as a cash-burning business, but he can see the light at the end of the tunnel.

"Breakeven is now closer for this business, with a net loss after tax of just $1.19 million in fiscal year 2022."

Bromley's peers are more convinced about this ASX share, with four out of five analysts currently surveyed on CMC Markets recommending Polynovo as a strong buy.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO and Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Johnson & Johnson. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Mergers & Acquisitions

Own Sigma shares? Here's the latest on the Chemist Warehouse merger

One year ago today, the two companies announced plans to merge. We could now be just a few months away…

Read more »